2026년 2월 6일 · Unknown · financial · 출처 Yahoo Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Reckitt Benckiser’s fair value estimate has been nudged to £67.86 from £66.04, a small change that reflects shifting views on how its growth story in areas like emerging markets and portfolio focus might play out. While the discount rate is unchanged and revenue growth assumptions have only been tweaked, the updated target incorporates fresh research that balances enthusiasm about cleaner categories and execution with concern around ongoing reliance on mix and emerging markets. Read on to see what is driving this evolving narrative and how you can keep on top of future updates.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Reckitt Benckiser Group.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
Citi reinstated coverage on Reckitt Benckiser Group with a Buy rating on 14 January 2026, which signals confidence in the company’s ability to execute and grow from here, even if detailed reasoning is not disclosed in the summary provided. Jefferies raised its price target to 5,900 GBp from 5,500 GBp on 6 January 2026 and kept a Hold rating, citing higher confidence in mid term volume and mix growth in emerging markets, especially China, following the divestment of the Essential Home business. The Jefferies commentary points to cleaner focus after the Essential Home sale and improving growth momentum in emerging markets as key positives that could support the current fair value work you saw earlier. Even with a Hold stance, Jefferies acknowledges ongoing brand support and pricing discipline, which speaks to execution quality and cost awareness, although it also highlights that this can limit operating margin expansion.
🐻 Bearish Takeaways
RBC Capital downgraded Reckitt Benckiser on 14 January 2026, indicating a more cautious stance around the stock, though the brief summary provided does not specify the exact concerns behind the move. Jefferies, despite lifting its price target to 5,900 GBp, chose to remain at Hold, which suggests some reservations that a lot of the upside from emerging market volume and mix, as well as portfolio tidying, may already be reflected in the share price. Jefferies also flags that realistic pricing and ongoing brand support will contain operating margin, which ties back to questions about how much further earnings and valuation can stretch without compromising on investment behind the brands.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
Story Continues
LSE:RKT 1-Year Stock Price Chart
What's in the News
Reckitt Benckiser Group plans a stock split or significant stock dividend at a ratio of 1 to 1.04167, scheduled for 2 February 2026. This will adjust the number of ordinary shares you hold once it takes effect. Shareholders approved a special dividend of 235 pence per existing ordinary share at the General Meeting on 27 January 2026, confirming an additional cash return to investors. The company has outlined an intention to return about £1.6b to shareholders via this 235 pence special dividend, with payment expected on 20 February 2026 for shareholders on the UK register and from 27 February 2026 for ADR holders, subject to the remaining approvals and admission of the new ordinary shares. A special shareholders meeting was held on 27 January 2026 in London to vote on the special dividend and related share consolidation steps. At the same time, Reckitt’s Mucinex brand broadened its US offering with Mucinex Clear & Cool Saline Nasal Spray, supported by a Grand Central Station art installation created with 3D muralist Kurt Wenner.
How This Changes the Fair Value For Reckitt Benckiser Group
Fair value is now £67.86 compared with £66.04, reflecting a modest uplift in the implied equity value in the model. The discount rate is held at 7.07%, so the underlying risk and return assumptions used to discount future cash flows are unchanged. Revenue growth is set at 28.40% versus 28.89% previously, which is a fractional adjustment to the long term top line outlook built into the numbers. Net profit margin is shown at 17.26% versus 17.26% previously, effectively flat with only a marginally higher profitability assumption indicated in the model. The future P/E multiple is now 21.59x compared with 21.88x, a slightly more conservative earnings multiple applied to Reckitt Benckiser Group’s expected profits.
🔔 Never Miss an Update: Follow The Narrative
Narratives on Simply Wall St let you connect a company’s story with the numbers, by setting out your view on its future revenue, earnings and margins, then tying that to a fair value. They live in the Community page, are easy to follow, and update automatically as news or earnings arrive. This helps you compare Fair Value with the current share price and decide if it might be time to buy, hold, or sell.
If Reckitt Benckiser Group is on your radar, it is worth keeping up with the full story behind the latest fair value and analyst expectations in the original Narrative.
The current Narrative, “RKT: Future Returns Will Depend On Mix Execution And Shareholder Payouts”, lays out how emerging market expansion, product mix and portfolio focus link through to earnings forecasts and the £67.86 fair value. It spells out clear assumptions on revenue growth, margin progression to 17.1% and earnings of £2.6b by 2028, so you can compare your own expectations with the consensus view. It highlights key risks, from legal cases to execution on cost savings, so you can judge how these might affect the relationship between Fair Value and today’s price over time.
Curious how numbers become stories that shape markets? Explore Community Narratives
This article by Simply Wall St is general in nature. We …